JP5134551B2 - プロリン特異的プロテアーゼを含んでなる食品、その調製、および毒性またはアレルゲン性グルテンペプチドを分解するためのその使用 - Google Patents
プロリン特異的プロテアーゼを含んでなる食品、その調製、および毒性またはアレルゲン性グルテンペプチドを分解するためのその使用 Download PDFInfo
- Publication number
- JP5134551B2 JP5134551B2 JP2008552750A JP2008552750A JP5134551B2 JP 5134551 B2 JP5134551 B2 JP 5134551B2 JP 2008552750 A JP2008552750 A JP 2008552750A JP 2008552750 A JP2008552750 A JP 2008552750A JP 5134551 B2 JP5134551 B2 JP 5134551B2
- Authority
- JP
- Japan
- Prior art keywords
- proline
- food
- enzyme
- gluten
- specific protease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 235000013305 food Nutrition 0.000 title claims description 91
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 title claims description 87
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 title claims description 87
- 108010068370 Glutens Proteins 0.000 title claims description 60
- 235000021312 gluten Nutrition 0.000 title claims description 54
- 108091005804 Peptidases Proteins 0.000 title claims description 37
- 239000004365 Protease Substances 0.000 title claims description 35
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 26
- 102000035195 Peptidases Human genes 0.000 title description 27
- 102000004196 processed proteins & peptides Human genes 0.000 title description 18
- 238000002360 preparation method Methods 0.000 title description 12
- 231100000331 toxic Toxicity 0.000 title description 10
- 230000002588 toxic effect Effects 0.000 title description 10
- 230000000593 degrading effect Effects 0.000 title description 3
- 230000002009 allergenic effect Effects 0.000 title description 2
- 230000000694 effects Effects 0.000 claims description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 26
- 235000018102 proteins Nutrition 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 235000004213 low-fat Nutrition 0.000 claims description 22
- 208000015943 Coeliac disease Diseases 0.000 claims description 15
- 239000000839 emulsion Substances 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000004615 ingredient Substances 0.000 claims description 10
- 235000011194 food seasoning agent Nutrition 0.000 claims description 7
- 239000004278 EU approved seasoning Substances 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 235000015067 sauces Nutrition 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 201000004384 Alopecia Diseases 0.000 claims description 3
- 206010003805 Autism Diseases 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- 208000027932 Collagen disease Diseases 0.000 claims description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 3
- 206010062639 Herpes dermatitis Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 230000002411 adverse Effects 0.000 claims description 3
- 231100000360 alopecia Toxicity 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 3
- 241000228212 Aspergillus Species 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 102000012479 Serine Proteases Human genes 0.000 claims description 2
- 108010022999 Serine Proteases Proteins 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 208000020016 psychiatric disease Diseases 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 10
- 235000005911 diet Nutrition 0.000 claims 1
- 230000000378 dietary effect Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 description 103
- 108090000790 Enzymes Proteins 0.000 description 103
- 229940088598 enzyme Drugs 0.000 description 103
- 101710118538 Protease Proteins 0.000 description 47
- 239000000047 product Substances 0.000 description 25
- 210000001744 T-lymphocyte Anatomy 0.000 description 22
- 239000000523 sample Substances 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 230000002496 gastric effect Effects 0.000 description 15
- 230000004936 stimulating effect Effects 0.000 description 15
- 108010061711 Gliadin Proteins 0.000 description 13
- 239000008346 aqueous phase Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 235000019419 proteases Nutrition 0.000 description 12
- 210000002784 stomach Anatomy 0.000 description 11
- 238000009928 pasteurization Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 102000057297 Pepsin A Human genes 0.000 description 9
- 108090000284 Pepsin A Proteins 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 235000008429 bread Nutrition 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 description 9
- 108010050792 glutenin Proteins 0.000 description 8
- 101710088675 Proline-rich peptide Proteins 0.000 description 7
- 241000209140 Triticum Species 0.000 description 7
- 235000021307 Triticum Nutrition 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 229940111202 pepsin Drugs 0.000 description 7
- 101710087459 Gamma-gliadin Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 210000001198 duodenum Anatomy 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- 235000012041 food component Nutrition 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 239000005417 food ingredient Substances 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000010874 in vitro model Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000056251 Prolyl Oligopeptidases Human genes 0.000 description 4
- 235000011034 Rubus glaucus Nutrition 0.000 description 4
- 244000235659 Rubus idaeus Species 0.000 description 4
- 235000009122 Rubus idaeus Nutrition 0.000 description 4
- 229940124568 digestive agent Drugs 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 230000002183 duodenal effect Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 102000011632 Caseins Human genes 0.000 description 3
- 108010076119 Caseins Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 101710136733 Proline-rich protein Proteins 0.000 description 3
- 235000007238 Secale cereale Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- -1 transglutaminase Chemical class 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 229960001322 trypsin Drugs 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
- 102100037084 C4b-binding protein alpha chain Human genes 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108010010256 Dietary Proteins Proteins 0.000 description 2
- 102000015781 Dietary Proteins Human genes 0.000 description 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 2
- 102100020751 Dipeptidyl peptidase 2 Human genes 0.000 description 2
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 2
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 101001095266 Homo sapiens Prolyl endopeptidase Proteins 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010060860 Neurological symptom Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108700015930 Prolyl Oligopeptidases Proteins 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 206010037180 Psychiatric symptoms Diseases 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 108060008539 Transglutaminase Proteins 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 150000001323 aldoses Chemical class 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- UTXSFKPOIVELPQ-SFHVURJKSA-N benzyl n-[2-[(2s)-2-[(4-nitrophenyl)carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]carbamate Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC(=O)[C@H]1N(C(=O)CNC(=O)OCC=2C=CC=CC=2)CCC1 UTXSFKPOIVELPQ-SFHVURJKSA-N 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 235000021245 dietary protein Nutrition 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000012520 frozen sample Substances 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 235000008960 ketchup Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000013310 margarine Nutrition 0.000 description 2
- 239000003264 margarine Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 102000003601 transglutaminase Human genes 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- 235000012794 white bread Nutrition 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 241000532370 Atla Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101710087084 Dipeptidyl peptidase 2 Proteins 0.000 description 1
- 102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710191695 Glutamine-rich protein Proteins 0.000 description 1
- 108010047762 HLA-DQ8 antigen Proteins 0.000 description 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- PZQNFVCVNORNPG-UHFFFAOYSA-M [Na+].OP(O)([O-])=O.OP(O)(=O)OP(O)(O)=O Chemical compound [Na+].OP(O)([O-])=O.OP(O)(=O)OP(O)(O)=O PZQNFVCVNORNPG-UHFFFAOYSA-M 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000007824 aliphatic compounds Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- ARYTXMNEANMLMU-ATEDBJNTSA-N campestanol Chemical class C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]2(C)CC1 ARYTXMNEANMLMU-ATEDBJNTSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000006171 gluten free diet Nutrition 0.000 description 1
- 235000020884 gluten-free diet Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000019692 hotdogs Nutrition 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 210000003767 ileocecal valve Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 108010032563 oligopeptidase Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 235000013606 potato chips Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 108060006613 prolamin Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000009561 snack bars Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
- C12N9/62—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from Aspergillus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/001—Spread compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/10—Marmalades; Jams; Jellies; Other similar fruit or vegetable compositions; Simulated fruit products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/60—Salad dressings; Mayonnaise; Ketchup
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/06—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14002—Dipeptidyl-peptidase II (3.4.14.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21026—Prolyl oligopeptidase (3.4.21.26), i.e. proline-specific endopeptidase
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Seeds, Soups, And Other Foods (AREA)
- General Preparation And Processing Of Foods (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
Description
本発明は、プロリン特異的プロテアーゼを含んでなる食品、その調製、および毒性またはアレルゲン性グルテンペプチドを分解するためのその使用に関する。
小麦、大麦、ライ麦、スペルト小麦、およびライ小麦中に存在する一般的な食餌性タンパク質であるグルテンの摂取が、人によっては疾患を引き起こすことが知られている。グルテンはグルタミンとプロリンに富むグリアジンおよびグルテニンの複合混合物であり、いくつかの疾患を誘発する原因であると考えられる。それらのアミノ酸組成のために、これらのグルテンの特異的部分はヒト胃腸管内におけるタンパク質分解に抵抗する。その結果、特異的なプロリンに富むペプチドが蓄積でき、多様なこのようなグルテン由来ペプチドに対する不耐性などの望ましくない効果をもたらすかもしれない。例えばセリアック病を患っている患者において、グルテンの観察される毒性の原因であるペプチドのアミノ酸配列について記載されている(Arentz−Hansenら、J.Exp.Med.、2000年;6:337〜342頁;Vaderら、Gastroenterology、2002年;122:1729〜1737頁)。
現在、高水分活性を示し、大量の酵素安定剤を欠く食品中の成分として、プロリン特異的プロテアーゼを使用してもよいことが分かっている。このような製品は、関連酵素活性の劇的な損失なしに、低温殺菌して適切な貯蔵性を保証することさえできる。本出願では、サンドイッチの具と、トッピングと、調味料と、ソースと、様々な飲料と、低脂肪スプレッドなどのエマルジョンなどの食品中で、プロリン特異的プロテアーゼが十分に活性のままであり、胃においてプロリンに富むグルテン配列の適切な加水分解が達成されることが実証される。一般に、食品の味は酵素の存在によって影響または改変されない。
・プロリン特異的エンドプロテアーゼ活性を有し、
・国際公開第2002/45523号パンフレットの配列番号2と同一のアミノ酸配列を有するか、または国際公開第2002/45523号パンフレットの配列番号2の1〜526のアミノ酸と、少なくとも80%、好ましくは少なくとも90%のアミノ酸配列の同一性を有するアミノ酸配列を有する。アミノ酸配列間の同一性レベルは、国際公開第2002/45523号パンフレットの15頁で言及される方法によって判定される。
[酵素活性試験]
37℃でpH4.6のクエン酸/二リン酸ナトリウム緩衝液中において、スイス国ブーベンドルフ(Bubendorf,Switserland)のBachemからのCBZ−Gly−Pro−pNAを基質として使用し、A.ニガー(niger)プロリン特異的エンドプロテアーゼ活性を試験した。反応生成物を405nMで分光光度的にモニターした。405nmにおける時間内の吸光度増大が、酵素活性の尺度である。プロリンプロテアーゼ単位(PPU)は、規定条件下、基質濃度0.37mMのZ−Gly−Pro−pNAで、1分あたり1μmolのp−ニトロアニリドを放出する酵素量と定義される。
モノクローナル抗体ベース(mAB)競合アッセイを使用して、動的胃腸生体外モデルの可溶性画分中のグリアジンおよびグルテニン双方のT細胞刺激性エピトープの濃度を判定した。そのために50mMのpH7.0のNa2HPO4/NaH2PO4、150mMのNaCl、0.1%のトウィーン(Tween)−20、およびドイツ国ペンツベルクのロシェ・ダイアグノスティックス(Roche Diagnostics GmbH(Penzberg,Germany))からのプロテアーゼ阻害剤カクテル(完全)を含有する緩衝液中でサンプルを希釈した。アッセイを、以前に記載されたように(Spaenij−Dekkingら、(2004年)Gut 53、1267〜1273頁)、2回実施した。
動的胃腸生体外モデルの異なるサンプルの固体(沈殿物)画分中に存在するT細胞刺激性エピトープのレベルを判定するために、1D SDS−PAGE実験を実施した。固体画分を6×タンパク質サンプル緩衝液(60%グリセロール、pH6.8の300mMトリス、pH8.0の12mM EDTA、12%SDS、864mM 2−メルカプトエタノール、0.05%ブロモフェノールブルー)中で可溶化し、12.5%SDS−PAGEゲル上で泳動した。タンパク質を米国イリノイ州ロックフォードのピアス(Pierce(Rockford,IL,USA))からのインペリアルプロテインステイン(Imperial Protein Stain)を使用して直接視覚化し、またはα−およびγ−グリアジン(Spaenij−Dekkingら、(2004年)Gut 53、1267〜1273頁)、およびHMWおよびLMW−グルテニン(Spaenij−Dekkingら、Gastroenterology 2005年、797〜806頁)からの刺激性T細胞エピトープに特異的なmAbsを用いた、PVDF膜へのウエスタンブロット後に視覚化した。
抗体ベースのアッセイを作り出すために、Balb Cマウス中で既知のT細胞刺激性α−、γ−グリアジン、およびLMWグルテニンペプチドに対して、モノクローナル抗体を産生させた。マウス脾臓とマウス骨髄腫細胞系との融合後、抗体産生ハイブリドーマを得た。これらを限界希釈によってクローンし、これらの細胞によって分泌されたmAbsについて、mAb競合アッセイにおけるそれらの効用を試験した。各特異性毎に1つまたは2つの適切なmAbを選択し、異なるmAbによって認識されたエピトープを判定した(表1)。
[プロリン特異的エンドプロテアーゼの濾過滅菌]
濾過は、滅菌酵素に好ましい選択肢を提供する。滅菌する酵素溶液は、クロマトグラフィーでの純化後に得てもよく、酵素溶液は1種以上の溶剤またはその他の添加剤を含んでなって酵素活性を調節し、酵素をさらに安定化してもよい。適切な安定剤は、例えばソルビトールおよびグリセロールである。グリセロール溶剤は、酵素溶液の10〜70w/w%、またはより好ましくは30〜60%w/wの濃度で添加してもよい。
[プロリン特異的エンドプロテアーゼの不存在および存在下での動的胃腸生体外モデルにおけるパンの消化]
胃腸管を経由する食物の通過は非常に動的な過程であり、静的生体外モデルではシミュレートできない。オランダ国ザイスト(Zeist,The Netherlands)のTNOによって開発されたような動的胃腸生体外モデルは、胃および小腸内の連続動的過程を高度にシミュレートする実証された消化モデルである(Minekusら、ATLA、1995年、23、197〜209頁;Larssonら、J.Sci.Food.Agic.1997年、74、99〜106頁)。これらのモデルにおいて得られた結果は、ヒトおよび動物での研究において得られた結果と非常に良く似ていることが示されている。
[毒性グルテンエピトープの存在に関する生体外消化されたパンの試験]
食物サンプル中のグルテンペプチドの存在を測定するために使用できる、次の2つのタイプの試薬が利用できる。セリアック病患者の小腸から単離されたT細胞クローン、および様々なグルテンペプチドに特異的なモノクローナル抗体。T細胞クローンは、グルテンペプチドが疾患の素因をつくるHLA−DQ2またはHLA−DQ8分子と結合すると、これらに反応する。これらの炎症性T細胞応答は、セリアック病の根本原因と考えられる。α、γ−グリアジン、LMW−グルテニン、およびHMW−グルテニン中のペプチドに特異的なT細胞クローンは入手できる(Wal van de,Y.ら、Eur.J.Immunol.29、3133〜3139頁(1999年)およびVaderら、Gastroenterology、122;1729〜1737頁(2002年)参照)。T細胞刺激性α−グリアジン、γ−グリアジン、および低分子量(LMW)および高分子量(HMW)−グルテニンペプチドに特異的なモノクローナル抗体もまた入手でき、食物サンプル中のこれらのペプチドを検出するための競合アッセイに組み込まれている(Spaenij−Dekkingら、Gut:53、1267〜1273頁(2004年))。
[プロリン特異的エンドプロテアーゼと低脂肪スプレッド生産との適合性]
プロリン特異的エンドプロテアーゼ活性が、高温での乳化剤への曝露、および水/油エマルジョン中への組み込みを乗り切るかどうかを試験するために、次の試験を実施した。
[低脂肪スプレッドの水性相中のプロリン特異的エンドプロテアーゼの貯蔵性]
低脂肪スプレッドの水相中のプロリン特異的エンドプロテアーゼ貯蔵性を試験するために、pH4.5および水活性0.98を有する乳酸含有水相を調製した。水相の微生物汚染を防止するために、濃縮安息香酸ナトリウム溶液を濃度が600ppmに達するまで、無菌的に添加した。次に無菌濾過したプロリン特異的エンドプロテアーゼを酵素活性が15PPU/gに達するまで、無菌的に添加した。次にこの溶液を多数の小型無菌バイアルに分割した。これらのバイアルのいくつかを零下20℃に置いて基準とし、その他のバイアルは8℃および30℃に置いた。数週間毎に、様々なバイアル内で残留プロリン特異的酵素の活性を測定した。酵素活性は、材料と方法セクションで詳述された手順に従って測定した。
[酵素含有ラズベリートッピングを用いたトーストの生体外消化]
食物中の毒性グルテン分子の分解を促進するために、酵素含有トッピングを使用するという概念を例示するために、次の実験を実施した。最初に250mLの保存安定性ラズベリートッピングを調製した。204gの量の液体酵素濃縮物(12PPU/mL)に、20.7グラムのスクロース、1.0グラムのクエン酸、ジボーダン(Givaudan)からの0.02%のラズベリー香料(76525−36)、および20.7gの0.5%サッカリン水溶液を添加した。様々な成分の溶解後、イリノイ州のCP Kelcoからの3.11gのキサンタン(Keltrol RD)を添加して、注意深い撹拌によって溶解した。粘稠な塊の最終pHは3.7であり、最終酵素濃度は約9.8PPU/gトッピングであり、最終水分活性は約0.99であった。ベンゾエート濃度を約600ppmに調節した。同様にして、言及した全成分を含有するが、活性プロリン特異的酵素を含まないプラセボ製品を調製した。前の実験(実施例2および3参照)に関連して、純粋な非増粘酵素溶液もまた試験に組み込んだ。
Claims (14)
- 少なくとも0.85の水分活性を有し、活性プロリン特異的プロテアーゼを含んでなる低温殺菌食品であって、
調味料、トッピング、サンドイッチの具、ソース、またはスプレッドを含むエマルジョンである、食品。 - 少なくとも0.85の水分活性を有し、活性プロリン特異的プロテアーゼを含んでなり、それによって1w/w%未満のタンパク質またはペプチドを含んでなる食品であって、
調味料、トッピング、サンドイッチの具、ソース、またはスプレッドを含むエマルジョンである、食品。 - 無グルテン食品である、請求項1または2に記載の食品。
- 低脂肪スプレッドである、請求項1〜3のいずれか一項に記載の食品。
- 前記プロリン特異的プロテアーゼが1〜7のpH値で最適活性を有する、請求項1〜4のいずれか一項に記載の食品。
- 前記プロリン特異的プロテアーゼがアスペルギルス(Aspergillus)に由来する、またはセリンプロテアーゼのS28ファミリーに属する、請求項1〜5のいずれか一項に記載の食品。
- 前記プロリン特異的プロテアーゼが前記食品に添加されてから前記食品に低温殺菌が施される、請求項1〜6のいずれか一項に記載の食品を調製する方法。
- プロリン特異的プロテアーゼが低温殺菌食品に添加される、請求項1または2〜5のいずれか一項に記載の食品を調製する方法。
- 無菌のプロリン特異的プロテアーゼが低温殺菌食品に添加される、請求項7または8に記載の方法。
- 請求項1〜6のいずれか一項に記載の低温殺菌食品の製造におけるプロリン特異的プロテアーゼの使用。
- プロリンに富む食物によって引き起こされるあらゆる有害な効果を防止する、請求項10に記載のプロリン特異的プロテアーゼの使用。
- セリアック病またはそれと関連した障害の臨床症状を予防するための請求項10に記載のプロリン特異的プロテアーゼの使用。
- 前記食品がグルテン含有食物と一緒の摂取を意図するものである、請求項10〜12のいずれか一項に記載の使用。
- 前記有害な効果またはセリアック病に関連した障害が、I型糖尿病、疱疹状皮膚炎、腸癌、腸非ホジキンリンパ腫、過敏性腸症候群、自己免疫甲状腺炎、膠原病、自己免疫脱毛症、および自己免疫肝炎を含む自己免疫障害と、自閉症、統合失調症、ADHD、双極性気分障害、およびうつ病を含む精神障害とを含む、請求項11または12に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06101219.1 | 2006-02-02 | ||
EP06101219 | 2006-02-02 | ||
PCT/EP2007/000896 WO2007088062A2 (en) | 2006-02-02 | 2007-01-30 | Food product comprising a proline specific protease |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009525033A JP2009525033A (ja) | 2009-07-09 |
JP2009525033A5 JP2009525033A5 (ja) | 2011-12-22 |
JP5134551B2 true JP5134551B2 (ja) | 2013-01-30 |
Family
ID=36090926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008552750A Expired - Fee Related JP5134551B2 (ja) | 2006-02-02 | 2007-01-30 | プロリン特異的プロテアーゼを含んでなる食品、その調製、および毒性またはアレルゲン性グルテンペプチドを分解するためのその使用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20090304670A1 (ja) |
EP (1) | EP1978829A2 (ja) |
JP (1) | JP5134551B2 (ja) |
CN (1) | CN101511211A (ja) |
AU (1) | AU2007211641B2 (ja) |
BR (1) | BRPI0707440A2 (ja) |
CA (1) | CA2637701A1 (ja) |
IL (1) | IL193067A0 (ja) |
NZ (1) | NZ569989A (ja) |
RU (1) | RU2446210C2 (ja) |
WO (1) | WO2007088062A2 (ja) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6632429B1 (en) | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
US20070053895A1 (en) | 2000-08-14 | 2007-03-08 | Fallon Joan M | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
US8030002B2 (en) | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
US20090324730A1 (en) * | 2008-06-26 | 2009-12-31 | Fallon Joan M | Methods and compositions for the treatment of symptoms of complex regional pain syndrome |
US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
PL2318035T3 (pl) | 2008-07-01 | 2019-10-31 | Curemark Llc | Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego |
US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
WO2010080835A1 (en) | 2009-01-06 | 2010-07-15 | Curemark Llc | Compositions and methods for the treatment or the prevention oral infections by e. coli |
KR20170005192A (ko) | 2009-01-06 | 2017-01-11 | 큐어론 엘엘씨 | 스타필로코쿠스 아우레우스 감염의 치료 또는 예방 및 표면 상의 스타필로코쿠스 아우레우스의 박멸 또는 감소를 위한 조성물 및 방법 |
US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
WO2011050135A1 (en) | 2009-10-21 | 2011-04-28 | Curemark Llc | Methods and compositions for the prevention and treatment of influenza |
JP2013518589A (ja) | 2010-02-02 | 2013-05-23 | アマノ エンザイム ユーエスエー,リミテッド | グルテン不耐性に対するプロテアーゼの使用 |
EP2555792A4 (en) * | 2010-03-30 | 2013-11-06 | Alvine Pharmaceuticals Inc | PROTEASES DEGRADING GLUTEN |
US9267128B2 (en) | 2011-03-30 | 2016-02-23 | Alvine Pharmaceuticals, Inc. | Proteases for degrading gluten |
BR112013027034A8 (pt) | 2011-04-21 | 2018-01-02 | Curemark Llc | "compostos para o tratamento de transtornos neuropsiquiátricos." |
US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
US9867872B2 (en) | 2013-09-05 | 2018-01-16 | Dsm Ip Assets B.V. | Use of an acidic soft drink to enhance the efficacy of a gluten-digesting enzyme |
GB201320781D0 (en) | 2013-11-25 | 2014-01-08 | Univ Newcastle | Model Gut System |
EP3164500B1 (en) * | 2014-07-01 | 2019-12-25 | DSM IP Assets B.V. | Low gluten yeast hydrolysates |
JPWO2016071989A1 (ja) * | 2014-11-06 | 2017-08-17 | ヤヱガキ醗酵技研株式会社 | ヒト用食品添加剤、健康補助食品、および、体質改善方法 |
ES2559902B1 (es) * | 2015-11-11 | 2016-11-22 | Pevesa Biotech, S.A. | Procedimiento de reducción de contaminantes en materia vegetal proteica |
CN109430683B (zh) * | 2018-10-10 | 2022-05-27 | 宁波希诺亚海洋生物科技有限公司 | 去除麸质的复合酶制剂 |
US20200383351A1 (en) * | 2018-10-26 | 2020-12-10 | The Regents Of The University Of California | Use of proteolytic enzymes to enhance protein bioavailability |
CN109497529A (zh) * | 2018-12-18 | 2019-03-22 | 山西中谱安信质检技术服务有限公司 | 富含稀少糖和抗氧化活性物质酵素的低温发酵方法 |
US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
CN113151228A (zh) * | 2021-03-16 | 2021-07-23 | 李明达 | 一种病毒消杀用的复合酶制剂及其制备方法与应用 |
WO2023147350A1 (en) | 2022-01-26 | 2023-08-03 | Digestiva, Inc. | Blood glucose stabilizing methods and compositions |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06292505A (ja) * | 1993-04-09 | 1994-10-21 | Kanegafuchi Chem Ind Co Ltd | 水中油型乳化組成物及びその製造方法 |
US6447772B1 (en) * | 1999-10-01 | 2002-09-10 | Klaire Laboratories, Inc. | Compositions and methods relating to reduction of symptoms of autism |
US6251391B1 (en) * | 1999-10-01 | 2001-06-26 | Klaire Laboratories, Inc. | Compositions containing dipepitidyl peptidase IV and tyrosinase or phenylalaninase for reducing opioid-related symptons |
DE60103174T2 (de) * | 2000-12-07 | 2005-05-12 | Dsm Ip Assets B.V. | Verfahren zur verhinderung oder verminderung der trübung in getränken |
ES2347320T3 (es) * | 2000-12-07 | 2010-10-28 | Dsm Ip Assets B.V. | Hidrolizados proteicos enriquecidos en peptidos que tienen un resto de prolina carboxi terminal. |
AU2002325890B2 (en) * | 2001-07-18 | 2007-10-04 | Dsm Ip Assets B.V. | Process for the hydrolysis of milk proteins |
US8524225B2 (en) * | 2003-09-23 | 2013-09-03 | Dsm Ip Assets B.V. | Use of proline specific endoproteases to hydrolyse peptides and proteins |
JP4355592B2 (ja) * | 2004-02-23 | 2009-11-04 | 森永乳業株式会社 | 抗ウイルス剤 |
JP2005328738A (ja) * | 2004-05-19 | 2005-12-02 | Kikkoman Corp | 酵素混合物及び調味料 |
JP2008505653A (ja) * | 2004-07-12 | 2008-02-28 | ディーエスエム アイピー アセッツ ビー.ブイ. | 血圧降下タンパク質加水分解物 |
US20060210692A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Baby food composition |
-
2007
- 2007-01-30 EP EP07703225A patent/EP1978829A2/en not_active Withdrawn
- 2007-01-30 CA CA002637701A patent/CA2637701A1/en not_active Abandoned
- 2007-01-30 NZ NZ569989A patent/NZ569989A/xx not_active IP Right Cessation
- 2007-01-30 RU RU2008135467/10A patent/RU2446210C2/ru not_active IP Right Cessation
- 2007-01-30 BR BRPI0707440-9A patent/BRPI0707440A2/pt not_active IP Right Cessation
- 2007-01-30 JP JP2008552750A patent/JP5134551B2/ja not_active Expired - Fee Related
- 2007-01-30 AU AU2007211641A patent/AU2007211641B2/en not_active Ceased
- 2007-01-30 CN CNA2007800044845A patent/CN101511211A/zh active Pending
- 2007-01-30 US US12/162,512 patent/US20090304670A1/en not_active Abandoned
- 2007-01-30 WO PCT/EP2007/000896 patent/WO2007088062A2/en active Application Filing
-
2008
- 2008-07-24 IL IL193067A patent/IL193067A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20090304670A1 (en) | 2009-12-10 |
CA2637701A1 (en) | 2007-08-09 |
CN101511211A (zh) | 2009-08-19 |
IL193067A0 (en) | 2009-02-11 |
WO2007088062A3 (en) | 2008-09-12 |
WO2007088062A2 (en) | 2007-08-09 |
AU2007211641B2 (en) | 2012-09-06 |
RU2446210C2 (ru) | 2012-03-27 |
JP2009525033A (ja) | 2009-07-09 |
AU2007211641A1 (en) | 2007-08-09 |
RU2008135467A (ru) | 2010-03-10 |
EP1978829A2 (en) | 2008-10-15 |
NZ569989A (en) | 2012-11-30 |
BRPI0707440A2 (pt) | 2011-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5134551B2 (ja) | プロリン特異的プロテアーゼを含んでなる食品、その調製、および毒性またはアレルゲン性グルテンペプチドを分解するためのその使用 | |
US20240245761A1 (en) | Methods of treating celiac disease | |
RU2370279C2 (ru) | Применение пролинспецифичных эндопротеаз для гидролиза пептидов и белков | |
JP7369893B2 (ja) | グルテン不耐症及びそれから生じる障害を治療するための組成物及び方法 | |
EP2793605A1 (en) | Process for obtaining rice protein hydrolysates useful in the prevention and/or treatment of obesity | |
AU2012355650A1 (en) | Protease enzymes for increased protein digestion rate and absorption and methods of using the same | |
JP2011144167A (ja) | 血糖値降下剤及び血糖値降下飲食品組成物 | |
RU2352146C2 (ru) | Композиция (варианты) и пищевой продукт из овса | |
EP2003989A1 (en) | Process for the hydrolysis of milk proteins | |
EP0357776A1 (en) | Egg white hydrolyzate | |
JPWO2006106704A1 (ja) | 血中アルコール代謝改善組成物 | |
WO2014060495A1 (en) | Process for the production of an infant formula | |
MX2008009960A (en) | Food product comprising a proline specific protease, the preparation thereof and its use for degrading toxic or allergenic gluten peptides | |
JPH07215851A (ja) | 抗アレルギー剤及びその製造法 | |
JP2017511800A (ja) | α−グルコシダーゼに関連付けられる病的状態の予防及び/又は治療のための組成物 | |
JP7344722B2 (ja) | 構成行為改善用組成物 | |
EP4395563A1 (en) | Fungal enzyme mixtures and uses thereof | |
JP2023025199A (ja) | 血圧降下用及び/又は中性脂肪低減用の組成物 | |
Mitea et al. | Efficient degradation of gluten by a prolyl |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100113 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110615 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110802 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20111031 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120619 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120919 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121016 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121109 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151116 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |